InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-28.8%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by Whiting Samuel, Directeur Médical. Officer active across 2 companies, notably Millendo Therapeutics, Inc.. Cumulatively, 3 reports have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €16k. Activity tracked since 6 January 2022. The latest transaction was disclosed on 2 July 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Whiting Samuel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
4,672 股@ US$2.1339.1% 占其流量Common StockSEC:0001415889-24-019279:0
标准退出：2024年9月30日 (T+90)
1,700 股@ US$4.804843.8% 占其流量Common StockSEC:0001209191-22-002753:0
标准退出：2022年4月6日 (T+90)
201 股Common StockSEC:0001140361-21-022931:0
3 条申报中的 3 条
About Whiting Samuel
Whiting Samuel is the Chief Medical Officer at Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. In this role, he is responsible for the medical strategy and research initiatives of the companies. His expertise in the medical field allows him to lead innovative projects aimed at improving treatments for patients. He plays a key role in the development of new therapies.
